Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved...

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder.
• Caused by somatic mutations in the PIGA gene, leading to deficient CD55/CD59 expression on blood cells.
• Deficiency results in complement-mediated hemolysis, anemia, and thrombosis.

Purpose of the Study:

• To review the mechanisms of action of complement inhibitors for PNH.
• To focus on C3/C3b-targeted therapy, specifically pegcetacoplan.
• To provide insights into PNH molecular underpinnings through treatment profiles.

Main Methods:

• Narrative review of current PNH treatments.
• Analysis of complement inhibition at C5, C3, and alternative pathway initiation levels.
• Focus on approved PNH therapies including C5 inhibitors, C3/C3b inhibitors, and factor B/D inhibitors.

Main Results:

• Six complement inhibitors are currently approved for PNH.
• Treatments target distinct points in the complement activation pathway.
• Varying treatment profiles offer insights into PNH disease control.

Conclusions:

• Complement inhibitors offer diverse therapeutic strategies for PNH.
• Pegcetacoplan represents a key C3/C3b-targeted therapy.
• Understanding treatment mechanisms enhances PNH management and research.